Status:
COMPLETED
Nevanac 3-Month Safety Study With QID Dosing
Lead Sponsor:
Alcon Research
Conditions:
Cataract
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.
Eligibility Criteria
Inclusion
- Patients of any race or sex ages 10 years or older undergoing cataract extraction with planned implantation of a posterior chamber intraocular lens.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Under 10
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT00332774
Start Date
February 1 2006
End Date
December 1 2006
Last Update
March 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Contact Alcon for Trial Locations
Fort Worth, Texas, United States, 76134